IGC Pharma Inc (IGC)
NYSEAMERICAN: IGC · IEX Real-Time Price · USD
0.460
-0.021 (-4.37%)
At close: Jul 19, 2024, 4:00 PM
0.461
+0.001 (0.20%)
Pre-market: Jul 22, 2024, 4:06 AM EDT
IGC Pharma Revenue
In the fiscal year ending March 31, 2024, IGC Pharma had annual revenue of $1.35M with 47.64% growth. Revenue in the quarter ending March 31, 2024 was $295.00K with 77.71% year-over-year growth.
Revenue (ttm)
$1.35M
Revenue Growth
+47.64%
P/S Ratio
25.87
Revenue / Employee
$20,075
Employees
67
Market Cap
34.79M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | 4.07M | -1.04M | -20.41% |
| Mar 31, 2019 | 5.12M | 2.92M | 133.29% |
| Mar 31, 2018 | 2.19M | 1.61M | 277.86% |
| Mar 31, 2017 | 580.37K | -5.79M | -90.88% |
| Mar 31, 2016 | 6.37M | -1.31M | -17.10% |
| Mar 31, 2015 | 7.68M | 5.41M | 237.87% |
| Mar 31, 2014 | 2.27M | -5.76M | -71.69% |
| Mar 31, 2013 | 8.03M | 3.83M | 91.21% |
| Mar 31, 2012 | 4.20M | 125.63K | 3.08% |
| Mar 31, 2011 | 4.07M | -13.82M | -77.24% |
| Mar 31, 2010 | 17.90M | -17.44M | -49.35% |
| Mar 31, 2009 | 35.34M | 33.15M | 1,515.10% |
| Mar 31, 2008 | 2.19M | - | - |
| Mar 31, 2007 | 0 | - | - |
| Mar 31, 2006 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Exagen | 55.73M |
| Retractable Technologies | 40.20M |
| Aadi Bioscience | 23.84M |
| iCAD, Inc. | 19.63M |
| DarioHealth | 19.04M |
| IceCure Medical | 3.26M |
| Cyclo Therapeutics | 1.13M |
IGC News
- 3 days ago - IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target - Business Wire
- 12 days ago - Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile - Business Wire
- 26 days ago - IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease - Business Wire
- 4 weeks ago - IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets - Business Wire
- 5 weeks ago - IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol - Business Wire
- 7 weeks ago - IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1 - Business Wire
- 2 months ago - IGC Pharma to Attend BIO International Convention 2024 - Business Wire
- 3 months ago - IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two - Business Wire